Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Goldnboy1on Aug 02, 2023 11:22pm
353 Views
Post# 35570370

Comparing to $TRIL

Comparing to $TRIL

When $TRIL did their first big fundraising it was very similar to this. However for $100m Vs. $15m.

The same 15% over-allotment 30 day window was provided.

The stock ran to $10+ before Pfizer's involvement as shareholder was announced.

This $15m will not put the buyer over 10%. So there will likely be no disclosure.

I emailed the company first thing in the morning Monday. I offered a $250k-$500k order. My email didn't even get answered now three days later.

I believe the bought and USD nature of this raise means it is a major taking it all.

$TRIL did $100m but they were nearly broke.  With Cash in hand, the full over allotment and the warrants cashing $ONC will have about $65M.

If the PanCan trial is a half off trial the numbers make perfect sense.

Hopefully Friday when it closes the stock absolutely rockets now that someone massive is priced in and ready to get greedy on market.

I don't think we will get a name on close, but you never know.

This weeks price dip will look like a steal a month from now. Management conference call planned this month. Have to think some big statements will come on that call to kick us into high gear!

 

<< Previous
Bullboard Posts
Next >>